Breaking News

FDA Clears Opus Genetics’ IND Application for Gene Therapy Candidate for Rare Inherited Retinal Disease
FDA Clears Opus Genetics’ IND Application for Gene Therapy Candidate for Rare Inherited Retinal Disease Dec 05, 2022 According to a statement from Opus Genetics, the FDA has approved its investigational new drug (IND) application for a phase 1/2, first-in-human clini
Aldeyra Therapeutics Submits NDA for Reproxalap for Treatment of Signs and Symptoms of DED
Aldeyra Therapeutics Submits NDA for Reproxalap for Treatment of Signs and Symptoms of DED Nov 30, 2022 Aldeyra Therapeutics has submitted a new drug application (NDA) to the FDA for topical ocular reproxalap, an investigational new drug candidate for th

Industry News

Harrow Expands National Product Supply Agreement with iOR Partners
Harrow Expands National Product Supply Agreement with iOR Partners Dec 01, 2022 Harrow and iOR Partners have expanded their national product supply agreement to provide Harrow’s entire formulary compounded ophthalmic products to i
Ophthalmology Day Set to Take Place Virtually on November 29
Ophthalmology Day Set to Take Place Virtually on November 29 Nov 29, 2022 Global financial services firm BTIG announced that "Ophthalmology Day at BTIG" will take place on November 29, 2022. The virtual, 1-day event will inc

Popular

The Use of Durysta (Bimatoprost) and Its Effects
The Use of Durysta (Bimatoprost) and Its Effects Dec 06, 2022 Bimatoprost is a medicine that helps with high pressure in the eye (OCT) and open-angle glaucoma. When too much fluid builds up in your eyes the press
Retinal Pattern Dystrophies
Retinal Pattern Dystrophies Dec 05, 2022 Retinal pattern dystrophies, as the name implies, are a group of disorders characterized by diverse pigment deposition patterns in the macula's retina

Editor's Pick

What is a Trabectome? Is the Surgery Risky?
What is a Trabectome? Is the Surgery Risky? Dec 02, 2022 Trabectome surgery increases the amount of fluid exiting the eye, helping to lower the pressure of the eye.
What Is DURYSTA Implant?
What Is DURYSTA Implant? Dec 01, 2022 DURYSTA is a totally biodegradable implant applied to an eye affected by glaucoma or high eye pressure. It’s a drug under the class of Prostaglandin Analogs.
Genetics and Long Years of Schooling Can Lead to Myopia in Children
Genetics and Long Years of Schooling Can Lead to Myopia in Children Nov 28, 2022 Researchers have discovered five genetic variations that steadily increase children’s likelihood of developing nearsightedness the longer they attend school. These findings were published on November 17 in the open access journal PLOS Genetics.

ESCRS 2022

Special ESCRS Interview With Dr. Carlos Ruiz Lapuente
Special ESCRS Interview With Dr. Carlos Ruiz Lapuente Oct 04, 2022 Carlos Ruiz Lapuente is an experienced surgeon in combined procedures of cataract, glaucoma, and vitreoretinal diseases.
Interview: Co-Founder Morena Gomedi Unveils Details of Espansione Group’s Newest Technology
Interview: Co-Founder Morena Gomedi Unveils Details of Espansione Group’s Newest Technology Sep 21, 2022 Founded in 1981, Espansione Group designs and manufactures a wide range of innovative devices and solutions in the fields of ophthalmology and dermatology.
Several Satellite Symposia Planned for the 3rd Day of the ESCRS Congress
Several Satellite Symposia Planned for the 3rd Day of the ESCRS Congress Sep 18, 2022 The third day of the ESCRS Congress will be marked with several important satellite symposia, in which global eyecare companies will introduce case studies and clinical results of their newly-launched ophthalmic products with clinical experts.
Ophthalmology Breaking News Subscribe